Today, GSK plc (LSE/NYSE: GSK) announced a significant change in leadership, designating existing Chief Commercial Officer Luke Miels as CEO Designate. On January 1, 2026, Miels, a well-known and esteemed leader in the biopharma industry worldwide, will take on full responsibility as CEO and join the board.
The hiring signals the start of a significant strategic phase for GSK, which aims to reach over £40 billion in total sales by 2031 while concentrating on its revitalized portfolio of vaccines and specialty drugs.
After almost ten years of revolutionary leadership, incumbent CEO Dame Emma Walmsley will leave the Board on December 31, 2025, and Miels will take over as CEO. To guarantee a smooth transition, she will stay with the company until September 30, 2026.
Read More: GSK’s Gepotidacin Granted Priority Review by US FDA for Gonorrhoea Treatment
A New Leader for a Transformed Company
Since joining GSK in 2017, Luke Miels has played a significant role in shaping the business’s sales strategy, especially in expanding its portfolio of specialist medications in fields including respiratory and cancer. He has held senior leadership positions in the US, Europe, and Asia during his career. He has also held positions with well-known pharmaceutical companies like AstraZeneca, Roche, and Sanofi-Aventis.
On behalf of the Board, I want to thank Emma and acknowledge her outstanding leadership in delivering a strategic transformation of GSK, including the successful demerger of Haleon. GSK today is necessarily very different to the company she was appointed to nine years ago and has a bright and ambitious future. The company is performing to a new, more competitive standard, with performance anchored in a stronger portfolio balanced across specialty medicines and vaccines.
I am delighted to announce that Luke will be the next CEO of GSK. He has outstanding global biopharma development and commercial experience, together with a deep understanding of the company, its prospects and its people. He is extremely well placed to lead, deliver and surpass the ambitions we have set for GSK, and to generate new growth and value for patients and shareholders.
Jonathan Symonds
Read More: GSK Acquires Efimosfermin, Bolstering Liver Disease Pipeline with Potential Best-in-Class Treatment
Walmsley’s Legacy of Transformation
Dame Emma Walmsley oversaw a time of major strategic change that was followed by the changeover. The successful demerger of the consumer healthcare division, which produced the new, market-leading company Haleon, is a highlight of her career. She also oversaw a thorough improvement in the pipeline, portfolio, and operating performance of the business.
GSK Secures Japan Orphan Drug Designation for Risvutatug Rezetecan in Small-Cell Lung Cancer
GSK’s risvutatug rezetecan has officially secured Orphan Drug Designation from Japan’s MHLW for the treatment of small-cell lung cancer (SCLC). Supported by durable response data […]
Under Walmsley’s direction, GSK’s R&D has been revitalized, resulting in 15 significant pipeline opportunities that are now scheduled to launch between 2025 and 20
Last Modified:
